| Name | Title | Contact Details |
|---|---|---|
Tara Callahan |
Senior Director, Corporate Counsel Technical Operations | Profile |
Megan Duplanty |
Senior Director, Corporate Counsel, North America Commercial Operations | Profile |
Brad Glasscock |
Group Vice President, Head of Global Regulatory Affairs | Profile |
We are a biopharmaceutical company specializing in the development of novel therapeutics to treat rare metabolic diseases. Our lead product candidate is INZ-701, an enzyme replacement therapy (ERT) in the early stages of clinical development for the potential treatment of patients with a variety of calcification disorders linked primarily to mutations in the ENPP1 and ABCC6 genes, or ENPP1 Deficiency and ABCC6 Deficiency respectively. We have demonstrated proof of concept with INZ-701 in both GACI and ARHR2 two phenotypes of ENPP1 Deficiency.
At Tetracore, we focus on animal health, domestic preparedness, antibody, clinical, and immunology products. View our products online.
Limelight is a privately held, multi-platform, multi-disease biopharmaceutical company headquartered in Philadelphia, PA and Cambridge, MA
Ontario Genomics Institute is a Toronto, ON-based company in the Healthcare, Pharmaceuticals, & Biotech sector.
ProThera Biologics, LLC (Main) is a East Providence, RI-based company in the Healthcare, Pharmaceuticals, & Biotech sector.